Bevacizumab in Treating Patients With Advanced Solid Tumors

Sponsor
Herbert Hurwitz, MD
Study ID
NCT00416637
Phase
PHASE1
Status
Completed

Conditions

  • Unspecified Adult Solid Tumor, Protocol Specific

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some find tumor cells and kill them or carry tumor-killing substances to them. Others interfere with the ability of tumor cells to grow and spread. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor . PURPOSE: This phase I trial is studying how well bevacizumab works in treating patients with advanced solid tumors.

Key Dates

First listed
Dec 28, 2006
Start date
Jan 31, 2004
Status verified
Jul 2016
Primary completion
Mar 31, 2006
Completion
Mar 31, 2006

Study Design

Enrollment
27 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Bevacizumab (Avastin)
    Bevacizumab given and then BP checked and skin biopsies obtained.

Related Studies